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Abstract
Background To evaluate the feasibility of designing a
randomized controlled study whether open carpal tunnel
release (OCTR) surgery can be performed safely under
systemic anticoagulant therapy using acetylsalicylacid
(ASA) or acenocoumarol (ACM), this preliminary, obser-
vational study was performed.
Methods Prospectively, during 1 year, data were collected
from all patients who underwent conventional OCTR at the
neurosurgical department of the Canisius Wilhelmina
Hospital, Nijmegen, The Netherlands. Patients continued
anticoagulant treatment perioperatively.
Results A total of 364 patients were operated on, of whom
45 continued ASA and seven ACM treatment. Only one
patient using ASA complained of a postoperative subcuta-
neous hemorrhage. In the control group without anticoagu-
lants, none of the patients had a bleeding postoperatively.
Conclusion Continuation of anticoagulant treatment is safe
for OCTR. The adverse effects of stopping treatment for
surgery can be severe. As a result of this study, we have





Carpal tunnel syndrome (CTS) is the most common
compression neuropathy of the upper extremity [2]. For
the treatment of CTS, conservative and surgical options are
available. Conservative treatments include wrist splints and
corticosteroid treatments [10, 12]. In more severe cases of
CTS and when conservative treatment fails, surgical
treatment is indicated. Surgery consists of dividing the
transverse carpal ligament, reducing the pressure on the
nerve [13]. The general consensus on open carpal tunnel
release (OCTR) is confined to a 2 to 3 cm long incision in
the palm of the hand [6]. All overlying structures and the
transverse carpal ligament are divided. Alternatively, an
endoscopic release has recently been developed, but among
other alternatives has not resulted in improved overall
outcome except for earlier return to work and daily
activities in favor of endoscopic surgery with a mean
difference of −6 days [17].
Antiplatelets (AP) and anticoagulants (AC) are commonly
used for patients with cerebrovascular, cardiovascular and
peripheral vascular problems to prevent future thromboem-
bolic events. There is no clear consensus regarding the
perioperative management of AP or AC treatment for a
OCTR surgical procedure. Continuation of AP or AC
treatment for small surgery has been proven safe for several
indications in the field of cutaneous [1, 11], dental [14]a n d
cataract surgery [7].
In order to evaluate the feasibility of a randomized
controlled trial, we first wanted to investigate the magni-
tude of the problem and collect some data for the sample
size calculation. Therefore, we performed this observational
study.
Methods
Patients were referred because of an electrophysiological
confirmed diagnosis of CTS. The data from all patients who
were surgically treated for CTS from June 2008 till June
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continue AP or AC treatments perioperatively. For AC
therapy international normalized ratio (INR) values were
kept within the therapeutic values. An OCTR with a 3 cm
long incision in the palm of the hand was performed
according to previously described surgical procedure [6].
Bleeding was stopped using bipolar coagulation. All
patients received compression bandage for 24 h postoper-
atively, and postoperative instructions of care. Follow-up
was performed by phone 3 weeks postoperatively, and
patients with persisting symptoms or complaints were seen
at our outpatient department at 6 weeks postoperatively.
Complications of discontinuation of therapy were noted.
Results
A total of 364 patients underwent OCTR surgery. 45 patients
continued ASA treatment perioperatively and seven patients
continuedACM.Intraoperativebleedingwaseasilycontrolled
and postoperative bleeding was recorded in one patient who
used ASA. He complained of a subcutaneous hematoma, but
additional treatment was not needed. In the ACM-group,
postoperative bleeding did not occur. Patients without AC
treatment did not suffer from postoperative bleeding.
Discussion
Discontinuation of AP or AC treatment for OCTR is not
needed to avoid bleeding complications. In fact, it may
increase the risk on ischemic problems in patients already at
risk for thrombotic events [8, 18].
Although designed as an investigational study, one of the
major flaws of this study is the observational design.
However, we believe a randomized clinical trial (RCT) is
not justified for three reasons.
The first reason is related to the ischemic events that
may arise after discontinuation of AP or AC therapy.
Patients who would discontinue AP or AC treatment, would
be exposed to an increased risk of cardiovascular adverse
events. The risk on thromboembolic complications depends
on the etiology. The risk of recurrent venous thromboem-
bolism in the 3 months after proximal deep-vein thrombosis
is approximately 50% in the absence of anticoagulation;
one month of AC therapy reduces this risk to about 10%
and after 3 months of AC therapy the risk remains about
5% [8, 16]. In patients with nonvalvular atrial fibrillation
anticoagulant therapy has proven to reduce this risk with 66
%[ 5]. Although the exact risks on thromboembolic adverse
events after discontinuation of AP or AC therapy for
surgery are unknown, it has been estimated that stopping
anticoagulant treatment for major surgery may increase the
risk of postoperative thromboembolism a 100-fold [8].
Even in smaller, laparoscopic surgery the risk is 10-fold
increased [9]. In patients with a high risk on perioperative
thromboembolic events, prophylactic inferior vena cava
filter placement can be considered to reduce the risk of
recurrent thromboembolic disease [19]. An alternative to
AP or AC treatment can be the use of low-molecular weight
heparin bridging the perioperative period [8, 15]. Unin-
tended discontinuation of long-term oral anticoagulant use
after overnight or ambulatory procedures has been present
in up to 11.4 % of patients [3]. Future studies are necessary,
to identify the exact risk of adverse events after discontin-
uation of AP or AC therapy. Until then a risk-based
approach may be considered. As a result of the relatively
low risk of perioperative hemorrhage in the field of
cutaneous, dental and cataract surgery the surgical protocols
have been changed in favor of perioperative continuation of
anticoagulant therapy [1, 7, 11, 14]. The postoperative
readjustment of the therapeutic values of INR can be
troublesome after discontinuation of AC treatment. Patients
need blood to be drawn regularly and may have to change
the dose of anticoagulant treatment [8].
Clopidogrel is an antiplatelet agent with similar pharmaco-
dynamics as ASA. It selectively alters the ADP receptor on the
blood platelet resulting in lessened blood aggregation. Because
of its selective blocking, the agent has a higher antiplatelet
effect than ASA and is effective at a lower dose. In the field of
cardiovascular disease it has shown to significantly reduce new
ischemia in theacute state after myocardialinfarction compared
with ASA [4]. Although it is hard to compare AP agents with
AC counterparts, the general consensus is that AC, which is
directly involved in the coagulation cascade, has a stronger
anticoagulatory effect than AP agents. Although, in our patient
population no patients were on Clopidogrel, we hypothesize
that it is also safe to continue Clopidogrel perioperatively, as
we compare its effect on coagulation with ASA.
Secondly, in our series the magnitude of the clinical
problem is minimal. Thirdly, a large number of patients are
needed for a properly designed study. For example, to
establish a difference of 2% in postoperative bleeding—with
a α=0.05 and a power of 80%—about 500 (inclusion of
estimated lost to follow-up) patients are needed per group. As
a result, around 1,000 patients would be needed for a RCT.
As a result of the large number of patients needed to study
the effect of continuation of anticoagulant therapy perioper-
atively, as well as the risk of serious adverse events in
discontinuation of anticoagulants, combined with the minor
magnitude of the clinical problem a RCT is not feasible.
Instead, because of the slight risk of hemorrhage and the
absence of intervention as a result of it, we have changed our
surgical protocol for OCTR. Patients with chronic anticoag-
ulant treatment do not have to stop their anticoagulant therapy
for carpal tunnel release surgery.
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